DOUBLE-SPECIFIC ANTIBODIES AGAINST CALR MUTANTS CUT FROM CD3 AND PHARMACEUTICALS CONTAINING THESE ANTIBODIES

VN10061258BActive Publication Date: 2026-10-01JUNTENDO EDUCATIONAL FOUNDATION +1

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: VN1202301419
Authority / Receiving Office: VN · VN
Patent Type: Patents
Current Assignee / Owner
Filing Date: 2021-08-26
Publication Date: 2026-10-01
Estimated Expiration: 2041-08-26

Application Information

Patent Timeline

26 Aug 2021

Application

VN1202301419

01 Oct 2026

Publication

VN10061258B

Inventors: KOMATSU, Norio; ARAKI, Marito

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The invention relates to a highly specific, dual-action antibody that specifically binds to the mutant calreticulin protein and a pharmaceutical containing this antibody. This specific, dual-action antibody has a first domain that specifically binds to the mutant calreticulin protein and a second domain that specifically binds to the CD3 antigen.

Need to check novelty before this filing date? Find Prior Art